Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | C1S | P09871 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | SELL | P14151 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28382970 | 0.84 | ACHE (0.39) | ALDH1A1TSHRACHETPMTSMN1; SMN2 | |
| SCHEMBL28452721 | 0.80 | ALDH1A1 (0.42) | ALDH1A1TSHRACHETPMTPRSS1 | |
| SCHEMBL2885211 | 0.80 | ALDH1A1 (0.42) | ALDH1A1TSHRACHETPMTPRSS1 | |
| SCHEMBL8033135 | 0.75 | — | — | |
| SCHEMBL16351489 | 0.74 | RAPGEF4 (0.43) | RAPGEF4 | |
| SCHEMBL26115 | 0.73 | — | — | |
| SCHEMBL341533 | 0.73 | ALDH1A1 (0.67) | ALDH1A1TSHRACHETPMTSMN1; SMN2 | |
| SCHEMBL503226 | 0.72 | ALDH1A1 (0.47) | ALDH1A1TSHRACHETPMTSMN1; SMN2 | |
| SCHEMBL25219985 | 0.71 | ALDH1A1 (0.35) | ALDH1A1TSHRACHEPRSS1PRSS2 | |
| SCHEMBL667708 | 0.71 | ACHE (0.50) | ALDH1A1TSHRACHESMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1598053-B1 | Use of a composition containing at least one phosphine as majority reducing agent to remove the artificial colour of keratinic fibres | OREAL (FR) | 2006-12-20 | — | — | EP | claimed |
| EP-1598053-A1 | Use of a composition containing at least one phosphine as majority reducing agent to remove the artificial colour of keratinic fibres | L'OREAL (FR) | 2005-11-23 | — | — | EP | claimed |
| US-20050251928-A1 | Method for stripping artificial color from keratin fibers | L'OREAL (FR) | 2005-11-17 | — | — | US | claimed |
| EP-4509515-B1 | LIGAND COMPOUND, ORGANIC CHROMIUM COMPOUND, AND CATALYST COMPOSITION COMPRISING SAME | LG CHEMICAL LTD (KR) | 2026-04-29 | — | — | EP | disclosed |
| EP-4215537-B1 | LIGAND COMPOUND, ORGANOCHROMIUM COMPOUND, AND CATALYST SYSTEM COMPRISING THE SAME | LG CHEMICAL LTD (KR) | 2026-04-29 | — | — | EP | disclosed |
| EP-4700031-A1 | LIGAND COMPOUND, ORGANIC CHROMIUM COMPOUND, AND CATALYST COMPOSITION COMPRISING SAME | LG Chem, Ltd. (KR) | 2026-02-25 | — | — | EP | disclosed |
| EP-4700033-A1 | LIGAND COMPOUND, ORGANIC CHROMIUM COMPOUND AND CATALYST COMPOSITION COMPRISING SAME | LG Chem, Ltd. (KR) | 2026-02-25 | — | — | EP | disclosed |
| US-20250381558-A1 | Ligand Compound, Organic Chromium Compound, and Catalyst Compositions Containing the Same | LG CHEM, LTD. (KR) | 2025-12-18 | — | — | US | disclosed |
| US-20250368598-A1 | CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES | BHATTACHARYA SHRABANTI (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4559921-B1 | LIGAND COMPOUND, ORGANIC CHROMIUM COMPOUND AND CATALYST COMPOSITION COMPRISING SAME | LG CHEMICAL LTD (KR) | 2025-11-26 | — | — | EP | disclosed |
| US-20250333427-A1 | Ligand Compound, Organic Chromium Compound, and Catalyst Composition Including the Same | LG CHEM, LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| EP-1254885-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE SECONDARY ALCOHOLS HAVING NITROGENOUS OR OXYGENIC FUNCTIONAL GROUPS | Asahi Kasei Kabushiki Kaisha (JP) | 2002-11-06 | — | — | EP | disclosed |
| WO-2002014330-A1 | CYCLOALIPHATIC/AROMATIC DIPHOSPHINES AND USE THEREOF IN CATALYSIS | DEGUSSA AG (DE) | 2002-02-21 | — | — | WO | disclosed |
| US-6348612-B1 | FORM COMPLEXES USED AS CATALYSTS FOR ENANTIOSELECTIVE REACTIONS SUCH AS ASYMMETRIC HYDROGENATIONS, ENANTIOSELECTIVE HYDROGEN DISPLACEMENTS, ALLYLIC SUBSTITUTION REACTIONS | ROCHE VITAMINS INC. | 2002-02-19 | — | — | US | disclosed |
| US-6084133-A | REACTING A PHOSPHINE HALIDE WITH A METAL, THEN PROTONATION RESULTING DIORGANO-SUBSTITUTED METAL PHOSPHIDE; SIMPLIFICATION, NONTOXIC, EFFICIENCY | KANKYO KAGAKU CENTER CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| EP-0739333-B1 | SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS | DU PONT (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0864576-A1 | Novel amidophospine-phosphinite derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| US-5510507-A | COORDINATION CATALYSTS; EFFICIENT ENANTIOSELECTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-04-23 | — | — | US | disclosed |
| US-5481006-A | PREPARATION OF INTERMEDIATES FOR PHARMACEUTICALS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-01-02 | — | — | US | disclosed |
| US-5223632-A | 2,2'-BIS(DI-(3,5-DIALKYLPHENYL)PHOSPHINO)-1,1'-BINAPHTHYL AND TRANSITION METAL COMPLEX CONTAINING THE SAMD LIGAND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1993-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368598-A1 | CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES | CA4, CA12, CA14 | ALDH1A1 688/4885TSHR 4615/4885ACHE 2398/4885 |
| US-20250333427-A1 | Ligand Compound, Organic Chromium Compound, and Catalyst Composition Including the Same | OXER1, ORC3, CRKL | ALDH1A1 3554/4885TSHR 1944/4885ACHE 70/4885 |
| US-20250381558-A1 | Ligand Compound, Organic Chromium Compound, and Catalyst Compositions Containing the Same | EXOC1, OXER1, ORC3 | ALDH1A1 3116/4885TSHR 2040/4885ACHE 81/4885 |
| US-20050251928-A1 | Method for stripping artificial color from keratin fibers | KRT18, DSG1, JUP | ALDH1A1 4512/4885TSHR 4245/4885ACHE 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.